Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment

Cancer Discovery

Volumn 2, Issue 12, 2012, Pages 1109-1117

  Braas, Daniel ^a   Ahler, Ethan ^a   Tam, Brenna ^a   Nathanson, David ^a,b   Riedinger, Mirielle ^a   Benz, Matthias R ^b   Smith, Kathleen B ^a   Eilber, Fritz C ^a,b   Witte, Owen N ^a,b   Tap, William D ^a,b,c   Wu, Hong ^a,b   Christofk, Heather R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2' DEOXY 2' [18F] FLUOROARABINOFURANOSYL); ARGININE; ASCORBIC ACID; CHOLESTEROL SULFATE; CYTIDINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; GEMCITABINE; GLUTAMINE; HOMOCYSTEINE; RADIOPHARMACEUTICAL AGENT; SERINE; THYMIDINE; UNCLASSIFIED DRUG; URIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DEOXYCYTIDINE; FEMALE; HUMANS; LIPOSARCOMA; METABOLOMICS; MICE; TANDEM MASS SPECTROMETRY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871486372     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0197     Document Type: Article

References (30)

1. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011; 23: 373-8.
2. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009; 218: 292-300.
3. Hoffman A, Lazar AJ, Pollock RE, Lev D. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat 2011; 14: 52-66.
4. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev 2011; 11: 541-57.
5. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Exp Rev Anticancer Ther 2010; 10: 249-60.
6. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755-63.
7. Romeo S, Dei Tos AP. Clinical application of molecular pathology in sarcomas. Curr Opin Oncol 2011; 23: 379-84.
8. Nair-Gill E, Wiltzius SM, Wei XX, Cheng D, Riedinger M, Radu CG, et al. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest 2010; 120: 2005-15.
9. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-50.
10. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008; 105: 18782-7.
11. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 2012; 13: 270-6.
12. Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, et al. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A 2009; 106: 2847-52.
13. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, et al. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging 2011; 38: 711-21.
14. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 22-deoxycytidine analog. Nat Med 2008; 14: 783-8.
15. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A 2010; 107: 5551-6.
16. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41: 77-88.
17. Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 2011; 3: 153-64.
18. Funamizu N, Kamata Y, Misawa T, Uwagawa T, Lacy CR, Yanaga K, et al. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase. Pancreas 2012; 41: 107-13.
19. Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther 2012; 20: 1002-13.
20. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010; 116: 5200-6.
21. Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2n-deoxy-22-18F-fluoro-beta-D-arabinofuranosyl)cytosine and 1-(2--deoxy-2--18F-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med 2012; 53: 275-80.
22. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, et al. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 2011; 50: 95-112.
23. Smal C, Van Den Neste E, Maerevoet M, Poire X, Theate I, Bontemps F. Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes. Cancer Lett 2007; 253: 68-73.
24. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69: 4567-72.
25. Amsailale R, Van Den Neste E, Arts A, Starczewska E, Bontemps F, Smal C. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells. Biochem Pharmacol 2012; 84: 43-51
26. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012; 2: 260-9.
27. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
28. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
29. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003; 2: 131-7.
30. Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One 2011; 6: e25357.